Fully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-up
Open Access
- 1 May 2026
- journal article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (5) , 365
Abstract
Fully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-upKeywords
This publication has 18 references indexed in Scilit:
- BCMA CAR-T cells in multiple myeloma–ready for take-off?Leukemia & Lymphoma, 2023
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaNew England Journal of Medicine, 2023
- Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot studyThe Lancet Oncology, 2023
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2023
- A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trialsHaematologica, 2022
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myelomaBlood, 2021
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2021
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and managementBlood Reviews, 2019
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple MyelomaJournal of Clinical Oncology, 2018